Eli Lilly in the spotlight

Assessing latest data in Alzheimer's disease

Eli Lilly ($LLY) lifted the bio market last week after their amyloid-targeting therapy, donanemab, showed that it slowed cognitive and functional decline in a Phase 3 study of early Alzheimer's disease. Although data met the endpoints, there was some hair on it. We think the donanemab Phase 3 data was more validating for the Alzheimer’s market as a whol…